1. Home
  2. MRNA vs QXO Comparison

MRNA vs QXO Comparison

Compare MRNA & QXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MRNA
  • QXO
  • Stock Information
  • Founded
  • MRNA 2010
  • QXO 1988
  • Country
  • MRNA United States
  • QXO United States
  • Employees
  • MRNA N/A
  • QXO N/A
  • Industry
  • MRNA Biotechnology: Biological Products (No Diagnostic Substances)
  • QXO EDP Services
  • Sector
  • MRNA Health Care
  • QXO Technology
  • Exchange
  • MRNA Nasdaq
  • QXO Nasdaq
  • Market Cap
  • MRNA 13.4B
  • QXO 14.1B
  • IPO Year
  • MRNA 2018
  • QXO N/A
  • Fundamental
  • Price
  • MRNA $28.02
  • QXO $20.51
  • Analyst Decision
  • MRNA Hold
  • QXO Strong Buy
  • Analyst Count
  • MRNA 20
  • QXO 8
  • Target Price
  • MRNA $46.24
  • QXO $32.71
  • AVG Volume (30 Days)
  • MRNA 8.6M
  • QXO 6.3M
  • Earning Date
  • MRNA 08-01-2025
  • QXO 08-14-2025
  • Dividend Yield
  • MRNA N/A
  • QXO 127.74%
  • EPS Growth
  • MRNA N/A
  • QXO N/A
  • EPS
  • MRNA N/A
  • QXO N/A
  • Revenue
  • MRNA $3,078,000,000.00
  • QXO $1,947,673,000.00
  • Revenue This Year
  • MRNA N/A
  • QXO $12,667.04
  • Revenue Next Year
  • MRNA $10.04
  • QXO $62.24
  • P/E Ratio
  • MRNA N/A
  • QXO N/A
  • Revenue Growth
  • MRNA N/A
  • QXO 3309.07
  • 52 Week Low
  • MRNA $23.15
  • QXO $10.62
  • 52 Week High
  • MRNA $91.99
  • QXO $24.69
  • Technical
  • Relative Strength Index (RSI)
  • MRNA 46.33
  • QXO 50.43
  • Support Level
  • MRNA $25.30
  • QXO $19.49
  • Resistance Level
  • MRNA $27.08
  • QXO $21.39
  • Average True Range (ATR)
  • MRNA 1.33
  • QXO 0.91
  • MACD
  • MRNA -0.31
  • QXO 0.05
  • Stochastic Oscillator
  • MRNA 32.38
  • QXO 57.97

About MRNA Moderna Inc.

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

About QXO QXO Inc. Common Stock

QXO Inc provides technology solutions, primarily to clients in the manufacturing, distribution, and service sectors. It provides consulting and professional services, specialized programming, training, and technical support. It also offers solutions for accounting, financial reporting, enterprise resource planning, warehouse management systems, customer relationship management, business intelligence, and other applications.

Share on Social Networks: